Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Farmers Insurance
AstraZeneca
McKinsey
Daiichi Sankyo
Covington
Fuji
Teva
Johnson and Johnson

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,718,640

« Back to Dashboard

Which drugs does patent 7,718,640 protect, and when does it expire?


Patent 7,718,640 protects AVEED and is included in one NDA. There has been one Paragraph IV challenge on Aveed.

This patent has forty-eight patent family members in thirty-seven countries.

Summary for Patent: 7,718,640

Title:Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Abstract: The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
Inventor(s): Hubler; Doris (Jena, DE), Fricke; Sabine (Jena, DE), Ingwersen; Jan-Peter (Berlin, DE), Kuhnz; Wilhelm (Berlin, DE)
Assignee: Bayer-Schering Pharma AG (Berlin, DE)
Application Number:10/798,780
Patent Claim Types:
see list of patent claims
Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Endo Pharms Inc
AVEED
testosterone undecanoate
INJECTABLE;INTRAMUSCULAR022219-001Mar 5, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,718,640

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,338,395Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,718,640

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2007118196► Subscribe
Russian Federation2354381► Subscribe
Russian Federation2005131724► Subscribe
Serbia51537► Subscribe
Serbia20050702► Subscribe
Portugal1457208► Subscribe
Peru10652004► Subscribe
New Zealand542321► Subscribe
Norway335179► Subscribe
Norway20054711► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Fish and Richardson
Harvard Business School
Chubb
Teva
McKinsey
Moodys
US Department of Justice
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot